This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Incyte (INCY), Pfizer (PFE) and MBX Biosciences, Inc. (MBX)

Tipranks - Tipranks - Tue Jun 16, 3:56AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Incyte (INCY), Pfizer (PFE) and MBX Biosciences, Inc. (MBX).

Claim 55% Off TipRanks

Incyte (INCY)

In a report released today, Etzer Darout from Barclays maintained a Buy rating on Incyte, with a price target of $117.00. The company’s shares closed last Friday at $108.53.

According to TipRanks.com, Darout is a 5-star analyst with an average return of 24.7% and a 55.3% success rate. Darout covers the Healthcare sector, focusing on stocks such as First Tracks Biotherapeutics Inc, Protagonist Therapeutics, and Monopar Therapeutics Inc. ;'>

Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $111.47, which is a 3.4% upside from current levels. In a report issued on June 8, TipRanks – Anthropic also upgraded the stock to Buy with a $114.00 price target.

See today’s best-performing stocks on TipRanks >>

Pfizer (PFE)

In a report released today, Emily Field from Barclays maintained a Sell rating on Pfizer, with a price target of $25.00. The company’s shares closed last Friday at $26.21.

According to TipRanks.com, Field is a 3-star analyst with an average return of 1.4% and a 44.8% success rate. Field covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences. ;'>

Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $29.05.

MBX Biosciences, Inc. (MBX)

Barclays analyst Eliana Merle maintained a Buy rating on MBX Biosciences, Inc. today and set a price target of $70.00. The company’s shares closed last Friday at $35.51.

According to TipRanks.com, Merle is a 1-star analyst with an average return of -0.3% and a 38.1% success rate. Merle covers the Healthcare sector, focusing on stocks such as Sagimet Biosciences, Inc. Class A, Ultragenyx Pharmaceutical, and Madrigal Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for MBX Biosciences, Inc. with a $75.43 average price target, implying a 135.7% upside from current levels. In a report issued on June 8, LifeSci Capital also maintained a Buy rating on the stock with a $91.00 price target.

Read More on INCY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).